Education
About Us
Working with TipRanks
Follow Us
Codexis (CDXS)
NASDAQ:CDXS
Top Page
Codexis
(NASDAQ:CDXS)
Select Model
Select Model
Rating:50Neutral
Price Target:
$1.50
▲(2.04% Upside)
Action:ReiteratedDate:03/13/26
The score is held back primarily by weak financial performance (ongoing losses, cash burn, and rising leverage). Offsetting this are a constructive technical setup (price above key moving averages) and a cautiously positive earnings update driven by ECOsynthesis progress, improved margins, and a strengthened cash runway, though valuation support is limited due to negative earnings and no dividend.
Positive Factors
Revenue & Product Margins
Revenue rebounded meaningfully in 2025 and product gross margins expanded to ~64%. Sustained higher product margins improve unit economics and provide structural leverage as volume scales, increasing the chance that additional commercial contracts will flow more directly to operating profitability over time.
Non-dilutive Financing & Cash Runway
The Merck technology transfer delivered substantial non-dilutive capital and boosted cash to $78.2M, which management expects will fund operations and GMP capex through 2027. This materially reduces near-term refinancing risk and gives time to convert feasibility work into higher-margin, recurring revenue streams.
Platform Scale-Up & Commercial Pipeline
Concrete technical milestones, multiple CDMO partnerships and a 55-opportunity pipeline signal platform adoption. Progress scaling from 100g toward 0.5kg and planned GMP retrofits create multiple long-term commercialization pathways that can convert service work into recurring licensing and supply revenue.
Negative Factors
Sustained Cash Burn
Codexis continues to generate negative operating and free cash flow, with FCF deteriorating in 2025. Persistent cash burn forces reliance on external funding or milestone payments, constrains strategic optionality, and makes execution of capital-intensive GMP scale-up dependent on converting pipeline opportunities or securing additional financing.
Rising Leverage
Leverage has increased markedly over recent years, reflecting greater reliance on debt funding. Higher debt-to-equity reduces financial flexibility, raises interest and covenant risk, and magnifies the consequences of any revenue or margin setbacks during the multi-year GMP build and commercialization window.
ECOsynthesis Early-Stage & Revenue Mix
Current ECOsynthesis revenues are still service-heavy and largely feasibility work; higher-margin, multi-year licensing or commercial supply remains contingent on converting assessments. That conversion risk, combined with planned R&D and GMP capex, creates execution and timing risk for realizing durable, scalable revenue.
Codexis (CDXS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$133.58M
Dividend YieldN/A
Average Volume (3M)1.15M
Price to Earnings (P/E)―
Beta (1Y)1.78
Revenue Growth-17.87%
EPS Growth14.42%
CountryUS
Employees188
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.11
Shares Outstanding90,869,350
10 Day Avg. Volume1,704,148
30 Day Avg. Volume1,146,380
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.81
Price to Sales (P/S)2.02
P/FCF Ratio-5.96
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue2.20
Enterprise Value/Gross Profit2.77
Enterprise Value/Ebitda-5.17
Forecast
1Y Price Target
$6.50Price Target Upside342.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.4
Revenue Forecast (FY)$70.80M
Codexis Business Overview & Revenue Model
Company DescriptionCodexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
How the Company Makes MoneyCodexis makes money primarily through (1) revenue from the sale and supply of enzymes used in customers’ manufacturing processes and (2) collaboration-related revenue from providing enzyme engineering, development services, and licensing of its intellectual property and technology platform. In practice, this can include upfront payments when collaborations are signed, research and development funding or fees as work is performed, milestone payments tied to technical or commercial achievements, and royalties or other commercial payments when a partner’s product or process incorporating Codexis enzymes reaches commercialization. The mix of these streams depends on the company’s active customer programs and partnership agreements; specific counterparties, contract terms, and the relative contribution of each stream vary over time and are disclosed in company filings.
Codexis Earnings Call Summary
Earnings Call Date:Mar 11, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Positive
The call highlighted substantial technical progress and commercial momentum for the ECOsynthesis platform (notable scale-up milestones, ISO 9001 certification, CDMO agreements, and a 55-opportunity pipeline) and showed improved financial metrics (higher revenue, stronger product gross margins, reduced annual net loss, and a strengthened cash position aided by a ~ $37.8M Merck agreement). At the same time, important risks remain: ECOsynthesis revenue is currently service-heavy with limited margin contribution, full-year net loss persists, R&D investments and GMP capex will continue to pressure cash, and many commercial relationships remain in feasibility or assessment stages. Given the number and significance of technical and commercial achievements that materially de-risk the business combined with remaining near-term financial and execution uncertainties, the overall tone is cautiously optimistic.Q4-2025 Updates
Positive Updates
Strong Revenue Growth and Improved Product Margins
Quarter revenue increased to $38.9M from $21.5M (≈+81% YoY), and full-year revenue rose to $70.4M from $59.3M (≈+19% YoY). Product gross margin improved to 64% in 2025 from 56% in 2024 (+8 percentage points). Management expects gross margins to remain stable in 2026.
Material Non-Dilutive Financing from Merck
Signed a technology transfer agreement with Merck that contributed approximately $37.8M (also referenced as ~$38M) in non-dilutive capital in Q4 2025, materially strengthening the cash position.
Healthy Cash Position and Runway
Ended 2025 with $78.2M in cash, cash equivalents, and short-term investments, which management expects will fund planned operations and capex through 2027.
Concrete ECOsynthesis Technical Milestones and Scale-Up
Delivered 10 grams of commercially relevant siRNA using full sequential ECOsynthesis and are currently operating at 100-gram scale in the Eco Innovation Lab with a target of achieving ~0.5 kg (500 g) scale by year-end 2026. Additionally, a client used Codexis ligase to manufacture a 3 kg batch of siRNA via chemoenzymatic production.
Commercial Engagements and Partner Wins
Signed three CDMO agreements in 2025 (Bachem, Nitto Avecia, Axolabs) and announced an emerging biotech contract to supply 50 grams of fully enzymatic siRNA (a low seven-figure agreement split between services and product). Sales pipeline contains 55 opportunities across 40 companies, indicating strong market interest.
Quality and Infrastructure Progress
Modernized non-GMP production capability in Redwood City and achieved ISO 9001 certification; passed a facility and quality management inspection by a large pharmaceutical customer. Leased a GMP plant in 2025 with retrofit construction planned to begin H2 2026 and expected to be operational by end of 2027.
Improved Operating Profitability Metrics
Net loss for the full year narrowed to $44.0M from $65.3M in the prior year (improvement of $21.3M, ≈32.6% reduction in annual net loss). Quarterly results showed a positive net income of $9.6M compared with a prior-year quarter loss of $10.4M.
Negative Updates
Ongoing Full-Year Net Loss and Burn for 2025
Despite improvement, Codexis reported a full-year net loss of $44.0M for 2025, indicating continued negative profitability on a yearly basis and ongoing need to manage cash burn while investing in GMP capacity.
ECOsynthesis Business Still Early-Stage and Service-Heavy
Current ECOsynthesis activity is largely feasibility and services-based (limited gross-margin contribution today). Commercial-scale, higher-margin ECO product revenues remain contingent on converting feasibility work into multi-year licensing, clinical supply and commercial supply agreements.
Revenue Guidance Shows Modest Growth and H2 Concentration
2026 revenue guidance of $72M–$76M implies only modest growth versus $70.4M in 2025, and management expects revenue to be more heavily weighted toward the second half of 2026, increasing near-term timing risk.
Increased R&D Spend Year-over-Year (Full Year)
R&D expenses for the full year increased to $52.3M from $46.3M (≈+13% YoY), reflecting higher employee-related costs and lab supplies tied to platform development and scale-up.
One-Time Restructuring Charge and Ongoing Cost to Build GMP Capacity
Fourth-quarter 2025 included a one-time restructuring charge of $3.4M. Management plans significant capital expenditures to retrofit a GMP facility (construction starting H2 2026) which will increase near-term capex and requires careful funding management despite current cash runway.
Dependence on Large Partnerships and Milestone Conversions
Substantial portion of the recent revenue uplift derived from the Merck technology transfer agreement; long-term success depends on converting feasibility agreements and CDMO assessments into licensing, referral revenue-sharing, and commercial supply deals—outcomes that remain uncertain in timing and scale.
Unproven Clinical/Commercial Benefit of New Features
New technical advances such as stereochemical control have promising potential, but biological validation (preclinical/clinical) and customer adoption remain to be demonstrated; management plans data disclosure in 2026 (e.g., TIDES) but tangible commercial impact is not yet proven.
Company Guidance
Codexis guided 2026 revenue of $72–$76 million, with results expected to be skewed to the second half of the year (Q1 roughly in line with consensus), and said product gross margins should remain stable at ~64% (2025 product gross margin 64% vs 56% in the prior year); management expects combined operating expenses and capital expenditures in 2026 to be similar to 2025 after cost-savings from a Q4 restructuring ($3.4M charge). Key balance-sheet and cash metrics: $78.2 million in cash, cash equivalents and short-term investments at year-end 2025 (including the ~$37.8M Merck technology transfer), which they expect will fund operations and capex through 2027, and a 2025 revenue base of $70.4M (vs $59.3M in 2024). Operational and commercial targets for 2026 include scaling ECOsynthesis from current 100 g operations toward 0.5 kg by year-end, beginning GMP plant retrofit construction in H2 2026 to be fully operational by end-2027, pursuing additional licensing deals (one anticipated in 2026), and advancing a commercial pipeline of 55 opportunities across 40 companies (including a prototype 50 g, low‑seven‑figure contract).Codexis Financial Statement Overview
Summary
Revenue growth and strong gross margins are positives, but the company still posts sizable net losses, rising leverage, and sustained negative operating/free cash flow, indicating elevated financing and execution risk.Income Statement
Revenue rebounded in 2025 (+33% vs. 2024) after declines in 2023–2024, and gross margin is strong (2025 ~87%). However, profitability remains weak with sizable operating and net losses across all years shown (2025 net margin about -62% and losses were even deeper in 2023–2024). Overall, the business shows improving top-line momentum and solid gross economics, but operating costs still overwhelm revenue, keeping earnings firmly negative.28
Negative
Balance Sheet
Leverage has risen meaningfully: debt-to-equity increased from ~0.19 (2023) to ~0.89 (2024) and ~1.45 (2025), signaling a heavier reliance on debt funding. Returns on equity are consistently negative due to ongoing losses (roughly -87% in 2025). Equity remains positive, but the direction of leverage and persistent losses increase balance-sheet risk and reduce financial flexibility.35
Negative
Cash Flow
Cash generation is a key weakness. Operating cash flow and free cash flow are negative in 2023–2025, with 2025 free cash flow worsening to roughly -$23.8M (about -61% vs. 2024). While 2022 was an exception with positive operating cash flow and free cash flow, the more recent trend indicates ongoing cash burn, implying continued reliance on external financing if conditions don’t improve.22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 70.39M | 59.34M | 70.14M | 138.59M | 104.75M |
| Gross Profit | 55.95M | 43.06M | 57.33M | 100.56M | 82.55M |
| EBITDA | -30.04M | -58.52M | -49.28M | -26.31M | -16.75M |
| Net Income | -43.97M | -65.28M | -76.24M | -33.59M | -21.28M |
Balance Sheet | |||||
| Total Assets | 10.73M | 149.01M | 136.56M | 250.39M | 246.38M |
| Cash, Cash Equivalents and Short-Term Investments | 78.21M | 73.46M | 65.12M | 113.98M | 116.80M |
| Total Debt | 73.21M | 59.90M | 16.02M | 43.64M | 47.65M |
| Total Liabilities | 97.27M | 82.08M | 49.95M | 105.60M | 81.99M |
| Stockholders Equity | 50.53M | 66.93M | 86.61M | 144.80M | 164.39M |
Cash Flow | |||||
| Free Cash Flow | -23.85M | -53.72M | -57.06M | 2.98M | -28.09M |
| Operating Cash Flow | -19.38M | -49.41M | -52.64M | 11.28M | -14.27M |
| Investing Cash Flow | 23.50M | -56.98M | -4.86M | -13.58M | -21.42M |
| Financing Cash Flow | 27.93M | 60.52M | 8.17M | -575.00K | 3.77M |
Codexis Technical Analysis
Neutral
1.47
Price Trends
1.38
Positive
1.62
Negative
2.13
Negative
Market Momentum
0.05
Negative
57.50
Neutral
46.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CDXS, the sentiment is Neutral. The current price of 1.47 is above the 20-day moving average (MA) of 1.23, above the 50-day MA of 1.38, and below the 200-day MA of 2.13, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 57.50 is Neutral, neither overbought nor oversold. The STOCH value of 46.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CDXS.
Codexis Risk Analysis
Codexis disclosed 50 risk factors in its most recent earnings report. Codexis reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Codexis Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $264.95M | -3.25 | -22.37% | ― | 3.36% | 5.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $133.58M | -3.23 | -114.26% | ― | -17.87% | 14.42% | |
50 Neutral | $298.42M | -1.33 | -107.14% | ― | ― | -17.21% | |
50 Neutral | $224.06M | -3.95 | -5657.87% | ― | ― | 17.36% | |
50 Neutral | $569.65M | -0.10 | 274.58% | ― | ― | -1072.48% | |
49 Neutral | $190.33M | -1.44 | 279.62% | ― | ― | ― |
* Healthcare Sector Average
CDXS
Codexis
1.47
-1.26
-46.15%
RNAC
Cartesian Therapeutics
7.18
-7.42
-50.82%
CABA
Cabaletta Bio
3.10
1.43
85.63%
ELTX
Elicio Therapeutics
12.18
4.21
52.82%
VOR
Vor Biopharma
13.72
-2.81
-17.00%
OABI
OmniAb
1.83
-1.36
-42.63%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.